5 results
Primary: To evaluate the efficacy of repeated subcutaneous (SC) administrations of lanadelumab in preventing angioedema attacks in adolescents (12 to <18 years of age) and adults with non-histaminergic angioedema with normal C1-INH.Secondary…
The objectives of this study:• To generate the proof of concept for lanadelumab for treatment of symptoms of COVID-19 disease • To demonstrate its safety after intravenous administration.
To validate the use of single urethral sensor catheter in demonstrating urethral pressure variations during filling cystometryIncidence of significant urethral pressure variations during urodynamic filling phase measured with three urethral sensor…
Primary: To evaluate the long-term safety of repeated subcutaneous(SC) administrations of lanadelumab in adolescents and adults with nonhistaminergicangioedema with normal C1-INH
To evaluate the safety and tolerability of XXB750 in adult participants with chronic stable HFrEF/HFmrEF.